NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55513-0096-01 | 55513-0096 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Sept. 25, 2006 | Feb. 28, 2009 | No Longer Used | |||
55513-0096-91 | 55513-0096 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Sept. 25, 2006 | Feb. 28, 2009 | No Longer Used | |||
55513-0097-01 | 55513-0097 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Sept. 25, 2006 | Feb. 28, 2009 | No Longer Used | |||
55513-0097-91 | 55513-0097 | Darbepoetin alfa | Aranesp | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Sept. 25, 2006 | Feb. 28, 2009 | No Longer Used | |||
55513-0110-01 | 55513-0110 | Darbepoetin alfa | Aranesp | 300.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug. 14, 2006 | In Use | ||
55513-0111-01 | 55513-0111 | Darbepoetin alfa | Aranesp | 300.0 ug/.6mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug. 14, 2006 | In Use | ||
55513-0710-01 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | June 5, 2010 | In Use | |
55390-0014-02 | 55390-0014 | Dexrazoxane | Dexrazoxane | Ancillary Therapy | Chemoprotective | Detoxifying Agent | March 31, 2005 | May 31, 2012 | No Longer Used | ||
55390-0060-02 | 55390-0060 | Dexrazoxane | Dexrazoxane | Ancillary Therapy | Chemoprotective | Detoxifying Agent | March 31, 2005 | May 31, 2013 | No Longer Used | ||
38423-0110-01 | 38423-0110 | Dexrazoxane Hydrochloride | Totect | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Oct. 16, 2007 | July 31, 2014 | No Longer Used | ||
54868-4138-00 | 54868-4138 | Dolasetron mesylate | Anzemet | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 11, 1997 | June 30, 2010 | No Longer Used | |
54868-4138-01 | 54868-4138 | Dolasetron mesylate | Anzemet | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 11, 1997 | June 30, 2010 | No Longer Used | |
00051-0021-21 | 00051-0021 | Dronabinol | Marinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | July 13, 2010 | In Use | |
17478-0761-06 | 17478-0761 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 20, 2014 | In Use | |
17478-0762-06 | 17478-0762 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 20, 2014 | In Use | |
17478-0763-06 | 17478-0763 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 20, 2014 | In Use | |
54868-3084-00 | 54868-3084 | Dronabinol | Marinol | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Aug. 11, 1994 | March 31, 2014 | No Longer Used | |
54868-3084-01 | 54868-3084 | Dronabinol | Marinol | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Aug. 11, 1994 | March 31, 2014 | No Longer Used | |
54868-3084-02 | 54868-3084 | Dronabinol | Marinol | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Aug. 11, 1994 | March 31, 2014 | No Longer Used | |
54868-3189-00 | 54868-3189 | Dronabinol | Marinol | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 7, 2005 | June 30, 2011 | No Longer Used | |
54868-3189-01 | 54868-3189 | Dronabinol | Marinol | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 7, 2005 | June 30, 2011 | No Longer Used | |
54868-3189-02 | 54868-3189 | Dronabinol | Marinol | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 7, 2005 | June 30, 2011 | No Longer Used | |
54868-3189-03 | 54868-3189 | Dronabinol | Marinol | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 7, 2005 | June 30, 2011 | No Longer Used | |
54868-5929-00 | 54868-5929 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Aug. 19, 2008 | In Use | |
00093-5655-56 | 00093-5655 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct. 9, 2015 | In Use | |
00093-5655-98 | 00093-5655 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct. 9, 2015 | In Use | |
00378-8009-77 | 00378-8009 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | June 14, 2016 | Dec. 31, 2017 | No Longer Used |
00378-8009-93 | 00378-8009 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | June 14, 2016 | Dec. 31, 2017 | No Longer Used |
25000-0011-03 | 25000-0011 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | April 27, 2017 | In Use | |
25000-0011-07 | 25000-0011 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | April 27, 2017 | In Use | |
00002-6902-30 | 00002-6902 | Pirtobrutinib | JAYPIRCA | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Jan. 27, 2023 | In Use | |
00002-7026-60 | 00002-7026 | Pirtobrutinib | JAYPIRCA | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Jan. 27, 2023 | In Use | |
64842-0120-05 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb. 3, 2023 | In Use | |
64842-0120-04 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb. 3, 2023 | In Use | |
64842-0120-06 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb. 3, 2023 | In Use | |
72187-0102-03 | 72187-0102 | Elacestrant | ORSERDU | 345.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan. 27, 2023 | In Use | |
72187-0101-03 | 72187-0101 | Elacestrant | ORSERDU | 86.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan. 27, 2023 | In Use | |
50881-0006-03 | 50881-0006 | Retifanlimab-dlwr | ZYNYZ | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | March 22, 2023 | In Use | |
00006-3061-04 | 00006-3061 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 3, 2017 | May 25, 2021 | In Use |
00006-3061-02 | 00006-3061 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 3, 2017 | May 16, 2021 | In Use |
00078-1154-21 | 00078-1154 | Dabrafenib | Tafinlar | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | March 16, 2023 | In Use | |
00006-3061-00 | 00006-3061 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 3, 2017 | In Use | |
00006-3061-01 | 00006-3061 | Fosaprepitant Dimeglumine | Emend | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Feb. 3, 2017 | In Use | |
00143-9753-25 | 00143-9753 | Methylprednisolone Sodium Succinate | Methylprednisolone Sodium Succinate | 40.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Sept. 26, 2022 | In Use | |
00078-1161-47 | 00078-1161 | Trametinib | Mekinist | 0.05 mg/mL | Chemotherapy | MEK Inhibitor | BRAF | Oral | March 16, 2023 | In Use | |
00143-9754-25 | 00143-9754 | Methylprednisolone Sodium Succinate | Methylprednisolone Sodium Succinate | 125.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Sept. 26, 2022 | In Use | |
00078-0650-06 | 00078-0650 | Panobinostat | Farydak | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Feb. 23, 2015 | Jan. 31, 2023 | No Longer Used |
00093-5742-65 | 00093-5742 | Cyclosporine | Cyclosporine Modified | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | June 1, 2015 | Jan. 31, 2023 | No Longer Used |
00093-5741-65 | 00093-5741 | Cyclosporine | Cyclosporine Modified | 50.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | June 1, 2015 | Jan. 31, 2023 | No Longer Used |
00093-5742-19 | 00093-5742 | Cyclosporine | Cyclosporine Modified | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | June 1, 2015 | Jan. 31, 2023 | No Longer Used |
Found 10,000 results in 8 milliseconds — Export these results